Published in Am J Cardiol on March 01, 1992
QT dispersion. Br Heart J (1994) 1.62
QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Br Heart J (1994) 1.14
Adjustment of QT dispersion assessed from 12 lead electrocardiograms for different numbers of analysed electrocardiographic leads: comparison of stability of different methods. Br Heart J (1994) 1.06
Predictive value of myocardial delayed enhancement in Duchenne muscular dystrophy. Pediatr Cardiol (2014) 0.99
Dispersion of regional wall motion abnormality in patients with long QT syndrome. Heart (1998) 0.98
Ventricular anti-arrhythmic effects of heptanol in hypokalaemic, Langendorff-perfused mouse hearts. Biomed Rep (2016) 0.95
Computerised measurements of QT dispersion in healthy subjects. Heart (1998) 0.88
Dispersion of ventricular repolarisation: a marker of ventricular arrhythmias in patients with previous myocardial infarction. Heart (1997) 0.84
Dispersion of QT and QTc interval in healthy children, and effects of sinus arrhythmia on QT dispersion. Heart (1998) 0.82
Measurement error as a source of QT dispersion: a computerised analysis. Heart (1998) 0.82
Use of lead adjustment formulas for QT dispersion after myocardial infarction. Br Heart J (1995) 0.82
Effects of beta-adrenergic antagonists on the QT measurements from exercise stress tests in pediatric patients with long QT syndrome. Pediatr Cardiol (2003) 0.82
Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol (2006) 0.81
QT dispersion and left ventricular morphology in patients with hypertrophic cardiomyopathy. Heart (2003) 0.77
Cardiac repolarization changes in the children with breath-holding spells. Iran J Pediatr (2013) 0.75
Electrophysiological mechanisms of long and short QT syndromes. Int J Cardiol Heart Vasc (2016) 0.75
Congenital and drug-induced long-QT syndrome: an update. Neth Heart J (2004) 0.75
[Not Available]. Herzschrittmacherther Elektrophysiol (1998) 0.75
Doctor-patient communication: the Toronto consensus statement. BMJ (1991) 8.57
Cardiopulmonary resuscitation skills of preregistration house officers. Br Med J (Clin Res Ed) (1985) 8.45
Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ (1995) 6.28
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet (1999) 3.38
From glycogen to amylopectin: a model for the biogenesis of the plant starch granule. Cell (1996) 3.33
Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J (1994) 3.13
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation (1997) 2.95
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Starch granules: structure and biosynthesis. Int J Biol Macromol (1998) 2.83
Chlamydia pneumoniae and coronary heart disease. BMJ (1997) 2.73
Colour Doppler flow mapping. BMJ (1990) 2.69
Major complications of coronary arteriography: the place of cardiac surgery. Br Heart J (1990) 2.61
Left atrial appendage: structure, function, and role in thromboembolism. Heart (1999) 2.52
Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart (1997) 2.50
Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation (2001) 2.50
Nomenclature for aerobic and facultative bacteria. Clin Infect Dis (1993) 2.49
Cost implications of the British Pacing and Electrophysiology Group's recommendations for pacing. BMJ (1992) 2.42
Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol (1991) 2.42
Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 2.31
Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart (2002) 2.23
The QT interval. Prog Cardiovasc Dis (2001) 2.22
Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol (1994) 2.21
Atrial arrhythmias. Lancet (1993) 2.13
The rhythm of the heart in active elderly subjects. Am Heart J (1980) 2.02
Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf (2001) 2.02
Complete denervation of the heart in a child with congenital long QT and deafness. Am J Cardiol (1988) 2.00
Cardiac arrhythmia suppression trial and flecainide. Lancet (1989) 1.98
Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. Lancet (1989) 1.96
Potential candidates for pacemakers. Survey of heart block and sinoatrial disorder (sick sinus syndrome). Br Heart J (1978) 1.94
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J (2000) 1.92
Components of heart rate variability--what they really mean and what we really measure. Am J Cardiol (1993) 1.91
Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol (1992) 1.74
Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation (1998) 1.74
Effect of intravenous propranolol on QT interval. A new method of assessment. Br Heart J (1980) 1.71
Nomenclature for aerobic and facultative bacteria. Clin Infect Dis (1999) 1.70
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res (2000) 1.70
Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect (1995) 1.69
Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet (1988) 1.65
Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol (2000) 1.65
Classification of atrial fibrillation. Pacing Clin Electrophysiol (1997) 1.63
QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J (1996) 1.63
Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J (1989) 1.59
Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation (1989) 1.53
Limitations of rate response of an activity-sensing rate-responsive pacemaker to different forms of activity. Pacing Clin Electrophysiol (1988) 1.51
The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J (1984) 1.49
Catheter ablation for successful management of left posterior fascicular tachycardia: an approach guided by recording of fascicular potentials. Heart (1996) 1.47
Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants. Circulation (1992) 1.45
Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J (1998) 1.44
Atrial fibrillation begets trouble. Heart (1997) 1.43
Unrecognized dyslipoproteinemia in United Kingdom families recruited to a genetic register because of unexplained coronary heart disease. J Lab Clin Med (1994) 1.42
Do patients with neurally mediated syncope have augmented vagal tone? Am J Cardiol (1993) 1.41
Implantable cardioverter defibrillators and fitness to drive. Lancet (1994) 1.41
Effect of magnesium sulphate in patients with unstable angina. A double blind, randomized, placebo-controlled study. Eur Heart J (1997) 1.41
Influence of the infarct site on the identification of patients with ventricular tachycardia after myocardial infarction based on the time-domain and spectral turbulence analysis of the signal-averaged electrocardiogram. Clin Cardiol (1995) 1.41
Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br Heart J (1989) 1.40
The Percutaneous Cardiac Mapping and Ablation Registry: final summary of results. Pacing Clin Electrophysiol (1988) 1.39
Quantification of left ventricular function with contrast-enhanced harmonic colour Doppler and a semiautomated boundary detection algorithm in technically difficult patients: feasibility, accuracy, and inter-observer variability. Eur J Echocardiogr (2001) 1.39
Current concepts in atrial fibrillation. Br J Hosp Med (1993) 1.39
Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems? J Cardiovasc Electrophysiol (1999) 1.39
Predictive value of wavelet decomposition of the signal-averaged electrocardiogram in idiopathic dilated cardiomyopathy. Eur Heart J (2000) 1.39
Influence of posture and reference point on central venous pressure measurement. BMJ (1991) 1.39
Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions. Postgrad Med J (1985) 1.38
Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation (1992) 1.38
Successful radiofrequency ablation of accessory pathways with the first energy delivery: the anatomic and electrical characteristics. Eur Heart J (1996) 1.38
Selection of dichotomy limits for multifactorial prediction of arrhythmic events and mortality in survivors of acute myocardial infarction. Eur Heart J (1997) 1.38
The NASPE/BPEG generic pacemaker code for antibradyarrhythmia and adaptive-rate pacing and antitachyarrhythmia devices. Pacing Clin Electrophysiol (1987) 1.37
Rapid and safe termination of supraventricular tachycardia in children by adenosine. Lancet (1987) 1.35
Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J (1984) 1.35
Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. Am J Cardiol (1986) 1.30
Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. Cardiovasc Res (1988) 1.29
Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 1.29
Treatment of refractory supraventricular arrhythmias with flecainide acetate. Arch Dis Child (1987) 1.28
Effects of intravenous adenosine on antegrade refractoriness of accessory atrioventricular connections. Circulation (1991) 1.27
Heart rate variability. Clin Cardiol (1990) 1.27
Adenosine in the diagnosis of broad complex tachycardia. Lancet (1988) 1.27
Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J (1982) 1.26
Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol (1995) 1.26
Prognostic value of reduced heart rate variability after myocardial infarction: clinical evaluation of a new analysis method. Br Heart J (1991) 1.25